Consuming high amounts of sugar while undergoing antibiotic treatment may significantly worsen the disruption those pharmaceutical drugs cause to beneficial gut bacteria, according to the findings of a comprehensive new study.
The research sheds new light on the delicate and complex ecosystem of the human intestinal microbiome. This vast community of microorganisms has evolved alongside humans over millennia, performing vital biological roles that include aiding in food digestion, regulating immune system functions, and protecting against foreign invaders. However, while antibiotics remain among the most commonly prescribed medicines worldwide for fighting bacterial infections, they are inherently indiscriminate. In clearing out harmful pathogens, these powerful drugs frequently wipe out beneficial bacterial species as well. This collateral damage can destabilize the internal ecosystem, occasionally creating a biological vacuum that allows opportunistic and potentially dangerous species to gain a foothold and multiply.
According to researchers, a diverse microbiome is generally much better equipped to resist the expansion and colonization of harmful pathogens. When antibiotic treatments drastically reduce that internal biodiversity, the gut ecosystem is left in a fragile state, making the host significantly more vulnerable to secondary infections and disease.
Sugar Linked to Greater Microbiome Damage
To better understand how external factors might influence this vulnerable state, an interdisciplinary team of researchers from NYU Langone Health, City of Hope, and Memorial Sloan Kettering Cancer Center undertook a massive observational effort. The investigators closely monitored 9,419 individual meals consumed by 173 hospitalized cancer patients, simultaneously tracking biological changes in their gut microbiomes through regular sampling.
The results of the analysis revealed a striking mathematical correlation between dietary intake and microbial health. For every additional 100 grams of sugar consumed by a patient during the 48-hour window prior to medical treatment, the researchers observed an additional 21% decline in alpha diversity. Alpha diversity serves as a standard scientific metric used to measure the variety and richness of beneficial bacterial species residing within the gut.
These findings, which were published online in the journal Nature, also demonstrated that diets high in simple sugars combined with standard antibiotic regimens were closely associated with notable surges in Enterococcus faecium. This specific bacterial species has raised clinical concerns because it has been frequently linked to hospital-acquired infections that can prove exceptionally difficult to treat with conventional medications.
Laboratory experiments involving mice yielded remarkably similar results, reinforcing the human clinical data. Animals that were exposed to the antibiotic biapenem while simultaneously being fed a diet rich in sucrose experienced a dramatic 16.3-fold increase in their intestinal Enterococcus population by the third day of the observation period. By the sixth day, the bacterial burden had skyrocketed to 33.4 times higher than baseline levels.
Dr. Jonas Schluter, an assistant professor in the Department of Microbiology at NYU Langone Health and co-senior author of the study, emphasized the broader implications of the work for modern medicine. As the medical community continues to uncover how the unintended collateral damage inflicted by antibiotics on the microbiome contributes to various long-term health problems, identifying actionable factors to limit these risks becomes paramount. The study, which relied on the detailed logging of over 9,000 meals, suggests that modifying patient diets during and after a course of antibiotics—specifically by reining in the intake of sweets—could serve as a practical tool for mitigating that risk.
Why Researchers Studied Blood Cancer Patients
The investigative team deliberately chose to focus their efforts on individuals diagnosed with blood cancers. This specific patient demographic is uniquely suited for such an investigation because they frequently receive heavy courses of antibiotics during the course of their care, and their daily food intake can be meticulously monitored and recorded while they reside in the hospital environment. Researchers kept exhaustive logs of every meal consumed by the patients while simultaneously collecting daily microbiome samples.
This rare combination of highly detailed nutritional records and rigorous, high-frequency biological sampling ultimately turned the project into one of the largest and most comprehensive investigations of its kind ever conducted.
Dr. Marcel van den Brink, chief physician executive at City of Hope and co-senior author of the study, noted that the microbiome is rapidly emerging as a critical factor in overall cancer care. For patients undergoing intensive and taxing interventions such as bone marrow transplantation, maintaining a healthy diversity of the gut microbiome can carry profound implications for their clinical trajectories. Studies of this scale help physicians better understand how everyday factors, including basic nutritional choices, can affect a delicate biological balance that ultimately influences how patients respond to therapies, navigate their recoveries, and experience side effects.
Patients battling blood cancers who undergo stem cell transplants are frequently required to remain hospitalized for several consecutive weeks. During this extended stay, they routinely undergo intensive chemotherapy alongside broad-spectrum antibiotic therapy. Over that same timeframe, both their hospital diets and the composition of their gut microbiomes can undergo radical and dramatic shifts. Within this disrupted environment, opportunistic and potentially dangerous species like Enterococcus faecium find fertile ground to flourish once the surrounding microbial ecosystem has been heavily compromised.
Gut Microbiome Damage and Cancer Outcomes
The clinical stakes of these microbial shifts are particularly high for vulnerable patient populations. Jonathan Peled, associate director of the Center for Hematological Malignancies at Memorial Sloan Kettering Cancer Center and a co-senior author on the study, pointed out that microbiome injury is directly correlated with worse clinical outcomes, including elevated overall mortality rates and a higher incidence of severe infections, particularly among blood cancer patients. He added that an essential next step for the research community will be the design and execution of clinical trials to test whether short-term, targeted dietary interventions can measurably improve real-world clinical outcomes in these patients.
The researchers theorize that dietary sugars essentially act as an ecological amplifier for the disruption already initiated by antibiotics. Potentially harmful bacteria that manage to survive the onslaught of the drugs may be uniquely positioned to exploit these simple sugars, utilizing them as an energy source to rapidly expand their populations and outcompete any remaining beneficial microbes.
William Jogia, a doctoral student in Dr. Schluter’s laboratory at the Institute for Systems Genetics and the second author of the study, explained that the new work successfully identifies dietary sugars as an accelerator of antibiotic-induced microbiome degradation. While the data strongly indicate that cutting back on simple sugars may help limit microbiome injury, the researchers acknowledge that further investigation is required to determine the exact physiological pathways at play. Specifically, scientists still need to establish whether dietary sugar directly nourishes Enterococcus, indirectly weakens competing bacterial strains through metabolic shifts, or operates via an entirely different biological mechanism within the human body.
Ultimately, while the current findings strongly point toward the conclusion that reducing simple sugar consumption during and after antibiotic regimens could help protect the gut ecosystem from excessive damage, the authors emphasize that additional research is necessary. Future studies must confirm the precise biochemical pathways involved and definitively prove whether these dietary adjustments translate into tangible clinical benefits for patients.
The extensive research collaboration involved investigators from a broad consortium of prominent institutions, including NYU Langone Health, City of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, the University of Minnesota, and the Fred Hutchinson Cancer Center, among others. Financial support for the expansive project was provided by numerous grants from the National Institutes of Health alongside contributions from various private foundations and philanthropic organizations.
